A homogeneous high-DAR antibody-drug conjugate platform combining THIOMABTM antibodies and XTEN polypeptides
Neelie Zacharias,Vladimir Podust,Kimberly Kajihara,Douglas leipold,Geoffrey Del Rosario,Emily Dong,Maciej Paluch,David Fischer,Kai Zheng,Corinna Lei,Jintang He,Carl Ng,Dian Su,Luna Liu,Shabkhaiz Masih,William Sawyer,Jeff Tinianow,Jan Marik,Victor Yip,Guangmin Li,Josefa Chuh,John Morisaki,Summer Park,Bing Zheng,Hilda Hernandez-Barry,Kelly Loyet,Min Xu,Katherine Kozak,Gail Phillips,Ben-Quan Shen,Cong Wu,Keyang Xu,Shang-Fan Yu,Amrita Kamath,Rebecca Rowntree,Dorothea Reilly,Thomas H. Pillow,Andrew Polson,Volker Schellenberger,Wouter Hazenbos,Jack Sadowsky
DOI: https://doi.org/10.21203/rs.3.rs-356231/v1
2021-01-01
Abstract:Abstract Antibody-drug conjugates (ADCs) enable cell-specific delivery of small molecules and are validated anti-cancer therapeutics. One factor limiting ADC advancement and broader application is the drug-to-antibody ratio (DAR), which dictates the number of payloads that can be delivered per antibody. With few exceptions, efficacious ADCs with DAR > 4 are inaccessible due to aggregation or rapid clearance in vivo. Here, we report a versatile platform for the generation of homogeneous ADCs with DAR up to 18, combining Cys-engineered THIOMAB antibodies and XTEN polypeptides to give “TXCs”. We show that high-DAR TXCs are stable biochemically and in vivo. We demonstrate that two different cytotoxic TXCs directed toward a tumor xenograft and one TXC targeting Staphylococcus aureus have comparable pharmacokinetics, but significantly enhanced efficacy in vivo versus conventional low-DAR ADCs. Our data suggest that high-DAR TXCs may ultimately offer several advantages versus conventional ADCs, including increased therapeutic index and efficacious delivery of less potent payloads.